Elementary Laboratory Assays as Biomarkers of Ageing: Support for Treatment of COVID-19?

Ageing Biomarker Life expectancy Medical laboratory Senescence

Journal

Gerontology
ISSN: 1423-0003
Titre abrégé: Gerontology
Pays: Switzerland
ID NLM: 7601655

Informations de publication

Date de publication:
2021
Historique:
received: 12 02 2021
accepted: 19 05 2021
pubmed: 3 8 2021
medline: 21 10 2021
entrez: 2 8 2021
Statut: ppublish

Résumé

Youth, working age and the elderly: On a timeline, chronological age (CA) and biological age (BA) may dissociate; nosological entities manifest themselves at different BAs. In determining which disease corresponds to a given age decade, statistical registries of causes of death are unreliable and this does not change with SARS CoV-2 infection. Beyond adolescence, ageing metrics involve estimations of changes in fitness, including prediction models to estimate the number of remaining years left to live. A substantial disparity in biomarker levels and health status of ageing can be observed: the difference in CA and BA in the large cohorts under consideration is glaring. Here, we focus more closely on ageing and senescence metrics in order to make information available for risk analysis non the least with COVID-19, including the most recent risk factors of ABO blood type and 3p21.31 chromosome cluster impacting on C5a and SC5b-9 plasma levels. From the multitude of routine medical laboratory assays, a potentially meaningful set of assays aimed to best reflect the stage of individual senescence; hence risk factors the observational prospective SENIORLABOR study of 1,467 healthy elderly performed since 2009 and similar approaches since 1958 can be instantiated as a network to combine a set of elementary laboratory assays quantifying senescence.

Identifiants

pubmed: 34340235
pii: 000517659
doi: 10.1159/000517659
pmc: PMC8450824
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

503-516

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Thomas Lung (T)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Pasquale Di Cesare (P)

InnoBoost SA, Lausanne, Switzerland.

Lorenz Risch (L)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Urs Nydegger (U)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Martin Risch (M)

Kantonsspital Graubünden, Chur, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH